Phadia US Inc.
$339.5K 6,871 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
ALK-Abello, Inc
ALK-Abello, Inc reported $339,373.07 across General Payments, Research, and Ownership to 4,525 physicians and teaching hospitals across 4,525 transactions.
- $339.4K
- All-tracks total
- 4,525
- Transactions
- 4,525
- Recipients
- +$183.9K
- General Payments vs PY2023
ALK-Abello, Inc reported $339,373.07 across all CMS Open Payments tracks (General + Research + Ownership) to 4,525 physicians and teaching hospitals in Program Year 2024 - ranking #864 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $339,373.07, averaging $75.00 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer alk-abello-inc ALK-Abello, Inc
$339.4K · #864/1,925 · 0.0% industry · PY2024
- TOT $339.4K
- RANK #864
- SHARE 0.0%
- TXN 4,525
- RCP 4,525
- CAT 4
- GEN $339.4K
- ΔGEN +$183.9K
- TOP1 11.5%
- PY 2024
Volume peers
Nearest volume peer: Phadia US Inc. ($339.5K)
ALK-Abello, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ALK-Abello, Inc's CMS-reported General Payments increased by $183.9K (+118.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ALK-ABELLO, INCPY2023: ALK-ABELLO, INCPY2024: ALK-Abello, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $155,488.01
- PY2024
- $339,373.07
What the Data Shows for ALK-Abello, Inc
In Program Year 2024, ALK-Abello, Inc reported $339,373.07 in payments to 4,525 physicians and teaching hospitals across 4,525 individual transactions, an average of $75.00 per transaction and $75.00 per recipient. That total places ALK-Abello, Inc at rank #864 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Honoraria" leads the 4-category general-payment breakdown below at $160.4K (47.3% of General Payments, 146 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 4 types of general payments, ALK-Abello, Inc's largest category was "Honoraria" at $160.4K - 47.3% of General Payments.
ALK-Abello, Inc reports 4 general-payment categories - the top three are Honoraria (47.3%), Food and Beverage (31.9%), and Consulting Fee (10.6%). The remaining 1 category make up 10.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How ALK-Abello, Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $160.4K | 146 | 47.3% |
| Food and Beverage | $108.2K | 4,271 | 31.9% |
| Consulting Fee | $36.0K | 23 | 10.6% |
| Travel and Lodging | $34.8K | 85 | 10.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $126,220.21 (37.2%) of $339,373.07 in this company's General Payments records across 2,590 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ALK-Abello, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Lara Gross
$39,190.79 across 52 reported transactions
- 2
Jacqueline Eghrari-Sabet
$33,627.44 across 34 reported transactions
- 3
Michelle Yasharpour
$24,098.42 across 40 reported transactions
- 4
Jonathan Malka
$15,327.74 across 18 reported transactions
- 5
Gary Freed
$13,975.82 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ALK-Abello, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ALK-Abello, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ALK-Abello, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
UCB Biosciences Inc.
$337.8K 13 recipients
Compare payment profiles
Carl Zeiss Meditec AG
$341.0K 11 recipients
Compare payment profiles
Noven Pharmaceuticals, Inc.
$337.1K 658 recipients
Compare payment profiles
HemoSonics LLC
$336.6K 219 recipients
Compare payment profiles
Intuitive Surgical Operations, Inc.
$335.6K 0 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.